Progress in Nonmetastatic Prostate Cancer
Mené sur 1 401 patients atteints d'un cancer de la prostate résistant à la castration et non métastatique présentant une augmentation rapide du taux de PSA, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans métastase, et la toxicité de l'enzalutamide
Since 2010, the Food and Drug Administration (FDA) has approved five new drugs for the treatment of metastatic, castration-resistant prostate cancer on the basis of a primary end point of overall survival.1 Progress in the treatment of nonmetastatic prostate cancer has been slower. A series of phase 3 trials that were designed to investigate treatments for the prevention of bone metastases either were stopped early or did not reach their primary end point.2-4 In a later, placebo-controlled, phase 3 trial, denosumab significantly prolonged bone metastasis–free survival among patients with nonmetastatic, castration-resistant prostate cancer.5 However, in February 2012, an Oncology Drugs . . .
New England Journal of Medicine , éditorial, 2017